

Biosurveillance Data Submission 3 & 4: Overdose Data to Action in States (OD2A-S)


The OD2A-S Biosurveillance program supports collection and testing of leftover urine samples from patients presenting to the ED and ICU with a suspected overdose.

148 samples


were collected between 1st January 2026 and 30th June 2026 from **two participating hospitals**: Mary Greeley and the University of Iowa Hospitals and Clinics (UIHC).

Patient Demographics


Basic demographic information from de-identified urine samples was collected to better understand population differences.



more than one-quarter of samples were from patients aged **15-24**.




The majority of samples tested were from patients within the racial category of **White**.




Detection Patterns

Leftover urine samples were sent to the State Hygienic Laboratory for targeted testing using a validated CDC-specified panel of analytes. Non-targeted screening was also conducted to identify analytes, based on library matches, not included in the panel. These detections may represent emerging analytes in Iowa and elsewhere.


Multi analyte detection (≥2 analytes) occurred in 66% of samples [^]Includes metabolites




Distribution of substance classes: Opioids were the most common substance class among samples.



Most frequently detected from panel of analytes (validated analytes):
Nearly a quarter of samples tested positive for Fentanyl.



Most frequently detected non-targeted (unvalidated analytes):



*Tested only in Q4

+Samples could test positive to more than one substance so the total does not add up to 100%.

Importance of Biosurveillance



Protecting the community:
Early detection of emerging drug trends can prevent deaths.



Supporting patient care:
Enhanced toxicology informs clinical practice.



Transforming insight into impact:
Guides data driven prevention and treatment efforts.

Contact us at: hhs.iowa.gov or call toll free at 1-800-972-2017

This publication was supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS) as part of the Overdose Data to Action in States (CDC-RFA-CE-23-0002) cooperative agreement award totaling \$2,507,303 with 100% funded by CDC/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, CDC/HHS or the U.S. Government.